Cardiff Oncology, Inc. (CRDF)
| Market Cap | 115.55M -38.4% |
| Revenue (ttm) | 525,000 -10.6% |
| Net Income | -44.79M |
| EPS | -0.67 |
| Shares Out | 68.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,115,161 |
| Open | 1.670 |
| Previous Close | 1.670 |
| Day's Range | 1.605 - 1.690 |
| 52-Week Range | 1.480 - 4.555 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 7.69 (+355.03%) |
| Earnings Date | May 14, 2026 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR... [Read more]
Financial Performance
In 2025, Cardiff Oncology's revenue was $593,000, a decrease of -13.18% compared to the previous year's $683,000. Losses were -$45.88 million, 0.93% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CRDF stock is "Strong Buy." The 12-month stock price target is $7.69, which is an increase of 355.03% from the latest price.
News
Cardiff Oncology reports Q1 EPS (18c), consensus (12c)
“This quarter was marked by the positive data update from our randomized Phase 2 CRDF-004 trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer, along with key leadership additio...
Cardiff Oncology sees cash, equivalents funding operations into 1Q27
16:18 EDT Cardiff Oncology (CRDF) sees cash, equivalents funding operations into 1Q27
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range...
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announce...
Cardiff Oncology to present preclinical data on onvansertib
Cardiff Oncology (CRDF) will present new preclinical data in a poster at the American Association for Cancer Research Annual Meeting, taking place April 17-22 in San Diego, California. These data…
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for...
Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
Cardiff Oncology (CRDF) announced the appointment of Mani Mohindru as president and CEO, following her time as interim CEO, and that she will continue as a member of the board.
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Ope...
Cardiff Oncology Transcript: KOL event
KOLs reviewed promising phase II data for onvansertib plus FOLFIRI+BEV in first-line RAS mutated metastatic CRC, highlighting a 72% response rate, strong PFS trends, and favorable tolerability. The 30 mg dose will advance to phase III, addressing a major unmet need for this patient group.
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumor activity and reversal of resistance with PLK1 inhibition Preclinical results in therapy-resistant ...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Onvansertib, a selective PLK1 inhibitor, demonstrated a 72% ORR and promising PFS in first-line RAS-mutated mCRC, with no significant added toxicity. Plans are underway for a global phase III trial, with regulatory discussions and more data expected in the first half of the year.
Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler
Piper Sandler lowered the firm’s price target on Cardiff Oncology (CRDF) to $6 from $10 and keeps an Overweight rating on the shares. The firm notes Cardiff ended 2025 with…
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of FO...
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright
H.C. Wainwright says the selloff yesterday in shares of Cardiff Oncology (CRDF) brings an attractive entry point. The firm finds updated CRDF-004 trial results “highly encouraging.” It expects a more…
Cardiff Oncology Transcript: Study result
Promising phase II data show that onvansertib plus FOLFIRI-Bev achieved a 72.2% response rate and extended PFS in first-line RAS-mutated mCRC, with favorable safety. The 30 mg dose will advance to a registrational trial, with further data and regulatory updates expected in 2026.
Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down
Cardiff Oncology (CRDF) announced a leadership transition. Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim...
Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib
Cardiff Oncology (CRDF) announced a “positive” update from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard of care, SoC, regimens in pati...
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in pat...
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology initiated with an Outperform at Noble Capital
Noble Capital initiated coverage of Cardiff Oncology (CRDF) with an Outperform rating and $12 price target Cardiff is developing onvansertib for the treatment of multiple cancer indications, with the ...